Navigation Links
John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
Date:12/7/2010

latrexate Effective in Patients with T-cell Lymphoma who Fail ICE-Based Regimens? (Abstract number #1753; poster session, December 4, 5:30-7:30 p.m.)

Andre Goy, M.D., M.S., Deputy Director and Chief, Lymphoma and Director, Clinical and Translational Cancer Research, John Theurer Cancer Center, and colleagues analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) which led to the FDA approval of pralatrexate in September 2009.

The goal of the study was to determine the outcome of the subset of patients with Peripheral T-Cell Lymphoma (PTCL) who had previously received and failed or relapsed after ICE chemotherapy. ICE is a combination of ifosfamide, carboplatin and etoposide, currently used as standard salvage therapy in patients with PTCL in preparation of high dose therapy followed by autologous stem cell transplantation.

PTCL is an especially aggressive cancer that attacks immune cells that protect the body from viruses. It is typically resistant to second-line treatments, such as ICE regimens.

Forty percent of study patients treated with pralatrexate showed a partial or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.

"Given the results, we will continue to explore the role of pralatrexate in combination with other agents to build upon its single agent activity. Our investigation will include PTCL patients in relapse and in the frontline setting in an effort to improve outcomes," said Dr. Goy.

Response of Multiple Myeloma Patients to Carfilzomib After Other Treatments Have Failed (Abstract number 985; oral session, December 7, 7:30 a.m.)

A new proteasome inhibitor may hold hope for patients with multiple myeloma who have been treated unsuccessfully with other drugs. Dr. Siegel and colleagues conducted an open-label single-arm phase 2b study of carfilzomi
'/>"/>

Contact: Amy Leahing
amy.leahing@gmail.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
2. John Theurer Cancer Center to present innovative research at 2 surgical meetings
3. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
4. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
5. The John Theurer Cancer Center recognizes medical physics team for safety track record
6. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
7. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
8. John Theurer Cancer Center offers breakthrough radiation measurement technology
9. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
10. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
11. Daily Aspirin Linked to Steep Drop in Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... By Denise Mann HealthDay Reporter , , THURSDAY, ... of Americans take to help treat hip and knee ... increase risk for developing glaucoma, a small new study ... there is an increase of intraocular pressure (IOP) or ... of the leading causes of blindness. ...
(Date:5/23/2013)... 2013 Memorial Day Focus Spotlight on ... been a part of the U.S. Military for more ... preceding it, these men and women will be honored ... of America. As veterans transition to civilian life, ... the workplace chaplaincy world. , Marketplace Chaplains, America’s ...
(Date:5/23/2013)... “Talk. They Hear You.” a new national ... talk to children as young as nine years old ... by the Substance Abuse and Mental Health Services Administration ... SAMHSA’s 2013 National Prevention Week—an annual health observance dedicated ... and mental health issues. , SAMHSA’s latest report on ...
(Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
(Date:5/23/2013)... carries a poor prognosis, with limited treatment options. ... the way it,s supposed to. New research from Western ... chemotherapy, and identifies a mechanism to rectify that. ... and his team at Western,s Schulich School of Medicine ... to promote the death of cancer cells by binding ...
Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... have arisen about the best approach whether it is public ... that more people want public services offering better health care ... Queen Elizabeth Hospital is an example financial difficulty due to ... study reveals that the health care provided by the not-for-profit ...
... a well-known fact that nearly 1/3rd of our lifetime is ... important as the quantity. People who have odd working hours ... chronic sleep deprivation that is responsible for fatigue and other ... North Polar Region have for the first time shed light ...
... the University of Washington researchers between obesity and asthma. ... the Journal of Allergy and Clinical Immunology. Previous studies ... develop asthma. The new research reveals the common genetic ... ,The researchers led by Dr. Teal Hallstrand analyzed ...
... French are reluctant to place their orders for Christmas turkeys ... ,However, the dreaded disease has not stopped the British and ... year, say industry sources. ,In France, bulk ... orders, say industry sources. The consumer confidence seems to have ...
... on bird shows in Britain has been lifted on account of ... ,Various events such as pigeon racing, falconry and other bird shows ... bird flu scare in October which was detected in Eastern Europe ... now since no single case of bird flu was reported the ...
... regarding the Christmas dinner. Turkey still remains popular inspite of the ... risen by 25% in Britain. Supermarket owners say that the sales ... ,When bird flu was spreading and was in its peak ... sales will fall very sharply. ,But the health officials ...
Cached Medicine News:Health News:Reindeer Provide Valuable Insights Into Sleep Disorders 2Health News:Christmas turkey? Anyone? 2
(Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Horror stories related to medical equipment for new construction or ... of dollars are wasted, and delays in go-live dates can ... an independent nonprofit that researches the best approaches to improving ... 6 best practices to ensure a better outcome in a ...
... Oct. 28 DUSA Pharmaceuticals, Inc.® (Nasdaq GM: ... announced today that global sales volumes of the ... Photodynamic Therapy (PDT) technology platform, surpassed one million ... that dermatologists in the U.S. and abroad continue ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
...
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
Medicine Products: